Effect of N-terminal pro B-type natriuretic peptide levels on the efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of Japanese patients with uncontrolled essential hypertension: a subanalysis of the EXCITE-HT study

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

EXCITE-HT was a randomized, open-label, parallel-group study.

In this subanalysis, patients were divided into low and high NT-proBNP subgroups based on their baseline levels (<125 pg/mL and ≥125 pg/mL, respectively).

Who Took Part

The study group was 188 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the BNP (Nesiritide) study did not mask who received what.

The BNP (Nesiritide) group and the comparison group ran side by side rather than switching.

What Was Measured

In this subanalysis, patients were divided into low and high NT-proBNP subgroups based on their baseline levels (<125 pg/mL and ≥125 pg/mL, respectively).

Topics PubMed links to this paper include Natriuretic Peptide, Brain, Peptide Fragments, Hypertension, Antihypertensive Agents, Blood Pressure, Essential Hypertension and Trichlormethiazide.

The authors tagged it with the keywords Esaxerenone, Japan, Morning home blood pressure and NT-proBNP.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of BNP (Nesiritide) in 188 patients.

The publication is from 2026 (Hypertension research : official journal of the Japanese Society of Hypertension), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.